Due to their structure, chemically derived drugs such as small molecules can be readily characterized and produced with high purity on a large scale ([@A8]; [@A9]; [@A13]; [@A30]; [@A43]). In contrast, biologic drugs are large compounds produced in living organisms, e.g., viruses, bacteria, and eukaryotic cells, through recombinant DNA technology or controlled gene expression ([@A8]; [@A9]; [@A13]; [@A30]; [@A43]). The first biologic drugs were introduced in the 1980s, and many are proteins that are similar or identical to human proteins, e.g., insulin and growth hormone, or they are monoclonal antibodies targeted to specific proteins within the body ([@A8]; [@A13]). Due to the structural complexity of biologic drugs, small modifications to the compound or surrounding environment during the manufacturing process, storage, or handling can greatly impact their safety and efficacy ([@A8]; [@A9]; [@A13]; [@A30]).

Over 80% of the US biologic therapy revenue in 2015 was from biologic therapies used for oncology indications, and revenue is expected to grow due to the rising incidence of cancer and increased utilization of biologic medicines within the clinic ([@A23]). This trend is not restricted to the United States, and the global biologic therapy market for oncology is expected to reach \$100 billion by 2023 ([@A23]).

Biologic drugs are mainstay therapies in the treatment of several diseases, such as cancer, rheumatoid arthritis, and inflammatory bowel disease. Examples of biologics for oncology indications include antineoplastic monoclonal antibodies such as rituximab (Rituxan, also known as MabThera outside the United States), bevacizumab (Avastin), and trastuzumab (Herceptin); and hematopoietic growth factors such as epoetin (Epogen, Procrit) and filgrastim (Neupogen; [@A38]). Despite biologic medicines revolutionizing the treatment of cancer and chronic diseases, access to these agents can be restricted, e.g., due to availability, insurance coverage, and/or cost ([@A1]; [@A31]; [@A37]; [@A45]). However, patents and marketing exclusivity for many biologics have expired or will expire in the next several years ([@A40]). These factors provide impetus for the development of biosimilars.

In terms of clinical relevance, biosimilars are distinct from generic drugs and they cannot be considered generic equivalents of biologic drugs ([@A11]). Generic drugs are identical copies of their original drugs, whereas biosimilars are biologic products that are highly similar, but not identical, to a licensed reference biologic (or \"originator\") product, such that there are \"no clinically meaningful differences between the biologic product and the reference product in terms of safety, purity, and potency,\" notwithstanding minor differences in inactive components ([@A47]).

High-quality biosimilars that are safe and efficacious could potentially increase access to biologic treatments, leading to improvements in clinical outcomes for patients and health-care system efficiencies ([@A2]; [@A34]). Indeed, biosimilars are now available in many countries, including the United States, and their introduction has been linked with both increased patient access and cost savings ([@A28]). Due to the potential impact of biosimilars, oncology advanced practice providers must be well-equipped with knowledge regarding these therapies.

In the United States, advanced practice providers now constitute 22% of the health-care provider workforce ([@A29]). As of 2015, 17% of all retail prescriptions (676 million prescriptions) were written by advanced practice providers, which is a substantial increase from 9% of all retail prescriptions (327 million prescriptions) in 2010 ([@A29]). However, many health-care providers have limited awareness and minimal experience regarding biosimilars ([@A7]; [@A27]; [@A33]; [@A36]; [@A39]; [@A40a]). Therefore, as the use of biosimilars becomes more widespread, advanced practice providers should understand the development process for these agents and the role of biosimilars in increasing treatment options for patients. This review provides an overview of biosimilars and discusses the clinical considerations for oncology advanced practice providers.

DEVELOPMENT AND MANUFACTURING PROCESS OF BIOSIMILARS
====================================================

To understand why biosimilars are distinct from generic drugs, it is helpful to first consider how biologic products and small-molecule, chemically derived drugs differ with respect to their fundamental properties and manufacturing processes ([Figure 1](#F1){ref-type="fig"}). In terms of structure and size, small-molecule drugs are simple structures with low molecular weight, whereas biologic products have high molecular weight and complex structures and, on average, are 100- to 1,000-fold larger than small-molecule drugs ([@A3]; [@A8]; [@A9]; [@A13]; [@A30]; [@A43]).
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In terms of manufacturing and production, small-molecule drugs are produced using chemical synthesis with recognized, easily obtained reagents. In comparison, the development of biologic products is significantly more complex, involving multiple stages, each with the potential to impact the final product ([Figure 2](#F2){ref-type="fig"}; [@A3]; [@A8]; [@A9]; [@A13]; [@A30]). First, the relevant protein sequence is cloned, inserted into a vector, and transfected into a host cell; the host cell can be bacterial or eukaryotic. Next, through cell screening and selection, a master cell line is established; this master cell line should express the recombinant protein in sufficient amounts and with the necessary posttranslational modifications. Additional cells are then cultured in substantial quantities using optimal growth conditions, followed by large-scale protein purification steps. Thereafter, the three-dimensional structure, uniformity, heterogeneity, and potency of the protein product is examined using a variety of sensitive analytical techniques, as well as functional bioassays. Finally, the formulated biologic drug is packaged, stored, and distributed under optimal environmental conditions to ensure the integrity and stability of the product ([@A3]; [@A8]; [@A9]; [@A13]; [@A30]).
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The protein structure of biologic products can be affected by a variety of factors, including, but not limited to, alterations to the primary amino acid sequence, oligomerization, glycosylation, protein folding, and environmental factors such as temperature and moisture ([@A8]; [@A9]; [@A13]; [@A30]). Consequently, the safety and effectiveness of the biologic product can be affected by alterations in the manufacturing process; for example, changes to the expression system (e.g., use of a different vector), modifications to the culture conditions or purification methods (e.g., changing growth media, reagents, or operating methods for optimization or economic reasons), upscaling of the process for large-scale manufacturing of the product, or modulation of storage and packaging conditions (e.g., using different stabilizers, buffers, or environmental factors; [@A8]; [@A9]; [@A13]; [@A30]).

Many of these factors have the potential to influence the immunogenicity of biologic products. Immunogenicity is the ability of a substance to elicit an immune response. There may be no clinical consequence for developing an immune response to a biologic product. However, for biologic products, including biosimilars, the presence of antibodies can sometimes be associated with immune-related adverse events, reduced or increased efficacy, or neutralization of the endogenous protein ([@A6]; [@A8]; [@A43]; [@A44]; [@A45]). Therefore, biologic products are more sensitive to changes in manufacturing, storage, and handling conditions, and have a higher immunogenic potential, compared with small-molecule drugs ([@A6]; [@A8]; [@A43]; [@A44]; [@A45]).

Due to the comparative ease of production, it is possible for manufacturers of small-molecule drugs to produce generic versions that contain an identical active ingredient to that of the corresponding originator product. These can be produced in large quantities and with high purity and stability. In contrast, and due to the complexities and proprietary nature of manufacturing conditions, it is likely not possible for the originator biologic product to be duplicated precisely, and some heterogeneity will almost certainly exist between the biosimilar and the reference product ([@A3]; [@A8]; [@A9]; [@A13]; [@A30]; [@A43]). Furthermore, prior to biosimilar development, the originator product must be fully characterized in terms of its structural, physicochemical, and biologic properties. Due to the larger size and greater complexity of the reference biologic product, it is more challenging to achieve this compared with development of a small-molecule generic drug. Several layers of protein structure, from the primary amino acid sequence through to the higher-order folding of the protein, as well as posttranslational modifications, must be fully understood and characterized, as any modifications could introduce variability in terms of structure, function, purity, and immunogenicity ([@A3]; [@A8]; [@A9]; [@A13]; [@A30]).

REGULATORY APPROVAL PROCESS FOR BIOSIMILARS
===========================================

For small-molecule generic drugs, approval is obtained on the basis of demonstrating bioequivalence to the corresponding originator product using analytical testing and comparative bioavailability studies. Nonclinical (animal) and clinical studies are generally not required ([@A48]). The small-molecule generic drug approval process is not suitable for or transferrable to biosimilars, which involves a more extensive and rigorous comparison with the originator ([@A59]). The purpose is to establish a high degree of similarity to the originator rather than to demonstrate clinical safety and efficacy, which have already been established for the reference product ([@A58]). Any heterogeneity between the biosimilar and the originator is evaluated to ensure there are no meaningful differences in terms of physicochemical and biologic characteristics, efficacy, safety, immunogenicity, and purity.

Although some differences exist, regulatory requirements for the approval of biosimilars are generally consistent across the major regulatory guidelines, e.g., European Medicines Agency (EMA; [@A16]), the US Food and Drug Administration (FDA; [@A47]), and World Health Organization (WHO; [@A61]), as well as guidelines in other highly regulated markets, such as Canada and Japan ([@A26]; [@A35]). Biosimilar or biosimilarity as defined in the FDA guidelines means that \"the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components,\" and that \"there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product\" ([@A47]).

To demonstrate biosimilarity, several types of studies, performed in a stepwise manner, are required ([Figure 3](#F3){ref-type="fig"}; [@A16]; [@A47]; [@A61]). First, in vitro analytical studies are performed in order to demonstrate that the biosimilar is highly similar to the reference product in terms of structure (e.g., the same amino acid sequence), higher-order structure and posttranslational modifications, and function (e.g., similar response observed during target/receptor-binding or cell-based assays). If the biosimilar is a monoclonal antibody, additional assessments of antibody-dependent, cell-mediated cytotoxicity and complement-dependent cytotoxicity are generally required. The results from the structural and functional analyses form a much larger part of the regulatory approval application for biosimilars compared with reference biologic products ([@A3]). Next, if necessary, the analytical studies are followed by nonclinical animal studies to establish that the biosimilar has the same clinically relevant mechanism of action and functional activity, as well as similar toxicity, as the originator product. Finally, a tailored, comparative clinical trial program is performed to compare the pharmacokinetics, pharmacodynamics, clinical efficacy, clinical safety, and immunogenicity of the biosimilar to the reference product. The purpose of this program is to establish similarity between the two products, and it is not to duplicate the clinical trial program of the originator. The type of animal and clinical studies required for approval are dependent on several factors, such as the reference product and the preceding analytical data ([@A16]; [@A45]; [@A47]; [@A61]).
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Usually, a biosimilar's clinical trial program consists of two stages. First, pharmacokinetics and pharmacodynamics are assessed in a head-to-head clinical study, and this generally involves healthy volunteers. This is followed by an evaluation of efficacy, safety, and immunogenicity across one or more comparative trials in patients. Since the focus of the clinical trial program is to demonstrate biosimilarity, the trial design, sample size, and endpoints may differ from those of the reference product, and should address any remaining concerns surrounding product-related differences in efficacy and safety between the biosimilar and originator product ([@A45]).

The stepwise approach to establishing biosimilarity should demonstrate that any heterogeneity between the biosimilar and the originator product as a result of the biosimilar's unique manufacturing process does not result in significant alterations in structural and functional characteristics, or clinical pharmacology, efficacy, safety, or immunogenicity ([@A16]; [@A45]; [@A47]; [@A61]).

The data from all stages of development are important for regulatory approval and medical acceptance. Biosimilar approval is granted based on \"totality of the evidence\" ([@A47]). Although the provision of an extensive data package is required for biosimilar approval, the demonstration of a high degree of similarity between the biosimilar and reference product in analytical assessments provides the rationale for a reduced nonclinical and clinical dataset compared with that required for licensing an originator biologic product ([@A61]). Finally, it is important to note that although overall guidelines exist, biosimilar approvals are made on an individual case-by-case basis, and the developers of a biosimilar product work with regulatory agencies to establish the relevant analytical, nonclinical, and clinical studies required to support approval ([@A16]; [@A47]; [@A61]).

CURRENT STATUS OF BIOSIMILARS IN THE CLINIC
===========================================

As of November 2, 2018, 49 biosimilars are authorized in Europe, and 14 biosimilars are currently licensed in the United States. Additional biosimilar applications are under evaluation by the EMA and FDA, with many more in development. The first monoclonal antibody biosimilars were recently approved by the EMA, FDA, and regulatory agencies in other countries for the treatment of inflammatory diseases (e.g., rheumatoid arthritis and inflammatory bowel disease). These include biosimilars of infliximab (Remicade) and adalimumab (Humira; [@A4]; [@A15], [@A18]; [@A21], [@A22]; [@A49], [@A51]).

Epoetin, filgrastim, and pegfilgrastim biosimilars are available for use in supportive care in various regions worldwide ([Table 1](#T1){ref-type="fig"}). In Europe, there are currently five epoetin, seven filgrastim, two pegfilgrastim, one bevacizumab, and four trastuzumab biosimilars authorized for use in patients with cancer, as well as six rituximab biosimilars for patients with blood cancers and inflammatory conditions. The filgrastim biosimilar, Zarxio, was the first biosimilar to be licensed by the FDA in 2015 for supportive care in oncology ([@A46]). The bevacizumab biosimilar, Mvasi, was the first biosimilar licensed for the treatment of adult patients with certain colorectal, lung, brain, kidney, and cervical cancers in the United States ([@A54]). In the European Union and United States, patents for monoclonal antibodies used in the treatment of cancer have expired or will soon expire ([@A40]). As a result, more biosimilars for rituximab, trastuzumab, and bevacizumab will likely become available in the near future. Indeed, a number of biosimilars for these monoclonal antibodies are currently undergoing comparative clinical trials ([Table 2](#T2){ref-type="fig"}; [@A42]).

![Biosimilars Available for Use in Oncology Indications in Europe and the United States](jadp-09-699-g04){#T1}

![Biosimilars Available for Use in Oncology Indications in Europe and the United States (cont.)](jadp-09-699-g05){#T1b}

![Biosimilars Available for Use in Oncology Indications in Europe and the United States (cont.)](jadp-09-699-g06){#T1c}

![Biosimilars Available for Use in Oncology Indications in Europe and the United States (cont.)](jadp-09-699-g07){#T1d}

![Proposed Biosimilar Products in Development for Oncology With Registered Comparative Clinical Trials](jadp-09-699-g08){#T2}

CONSIDERATIONS AND IMPLICATIONS FOR ADVANCED PRACTICE PROVIDERS
===============================================================

As more biosimilars obtain regulatory approval and become available for use in clinical practice, advanced practice providers will play an important role in evaluating the treatment options available to patients, as well as understanding any differences between products in prescribing, handling, and/or storage. Furthermore, advanced practice providers will play a critical role in prescribing and providing patient education and awareness regarding biosimilars, in addition to the ongoing assessment and monitoring of biosimilars in the clinic. In order to perform these tasks effectively, clinicians must understand several key considerations regarding biosimilars ([Table 3](#T3){ref-type="fig"}).
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**Dosing and Route of Administration**

In addition to having similar efficacy and safety profiles to their originator products, biosimilars are required to have the same dosing and route of administration as the originator. This should facilitate the transition of biosimilars into the clinic and limit the introduction of different features that may alarm or confuse patients or practitioners ([@A58]). This is particularly important for any biosimilars that have to be self-administered by the patient, such as filgrastim.

**Naming of Biosimilars**

The naming of biosimilars is critically important because of its potential impact on the prescribing and dispensing of medicines, and many prescribing advanced practice providers rely on product names to distinguish among different products. Currently, there is no international consensus on the naming of biosimilars, although nomenclature requirements are consistent within each regulatory region ([@A9]; [@A16]; [@A42]; [@A45]; [@A55]; [@A58]; [@A61]). In the United States, the FDA guidance is for the biosimilar to bear a nonproprietary name that includes an FDA-designated distinguishing suffix (devoid of meaning and composed of four lowercase letters), e.g., infliximab-dyyb for Inflectra ([@A55]). As a result of inconsistent naming of biosimilar products across the major regulatory agencies, drug reporting confusion, misattribution of adverse events, and insufficient monitoring of safety could occur. One approach to assist clinicians with appropriate prescribing and dispensing, as well as adequate safety monitoring, could be to support the use of biosimilar names that are not only distinguishable from their originator products but also reflect the unique manufacturing process and origin of the biosimilar. Efforts are underway to harmonize nomenclature globally, and further developments are awaited.

**Product Labeling and Prescribing Information**

Consistent policies regarding product labeling and prescribing information do not exist across the regulatory agencies ([@A9]; [@A14]; [@A42]; [@A45]; [@A52]; [@A58]; [@A61]). This is a key consideration, as many health-care providers within clinical practice routinely use prescribing information or summaries of product characteristics as an up-to-date point of reference ([@A12]; [@A25]; [@A40a]). US Food and Drug Administration guidance states that the biosimilar label must incorporate any relevant data from the originator product labeling, with appropriate product-specific modifications, e.g., information regarding the safe and effective use of the biosimilar or specific storage or handling requirements ([@A52]). On the other hand, other guidelines (e.g., those from the WHO and EMA) advise that the labeling and prescribing information for biosimilars be as similar as possible, if not identical, to the originator ([@A14]; [@A61]). Consequently, the evidence supporting the approval of the biosimilar (e.g., analytical studies or head-to-head clinical studies) may not be readily available to advanced practice providers, or they may incorrectly assume that the data available for the originator were obtained for the biosimilar. A lack of understanding of these issues may contribute to questions surrounding biosimilar quality, efficacy, and safety, as well as negatively impact the ability of advanced practice providers to present clear information and guidance on biosimilars to patients and other health-care providers. In summary, advanced practice providers need to be aware of the requirements concerning biosimilar labeling and prescribing information in their country, and that they may need to consult the websites of the regulatory bodies to review the evidence used to support biosimilar approval.

**Extrapolation**

Extrapolation is the use of a biosimilar in an indication held by the reference product, but without comparative trial assessment of the biosimilar in that indication ([@A9]; [@A16]; [@A42]; [@A45]; [@A47]; [@A58]; [@A60]; [@A61]). The extent of extrapolation that is permitted varies among regulatory agencies and is assessed on a case-by-case basis ([@A9]; [@A45]). The purpose is to reduce or eliminate the need for unnecessary clinical studies of the biosimilar in multiple indications that are already approved for the originator. The EMA, FDA, and WHO regulatory guidelines permit extrapolation provided that there is appropriate scientific justification and the totality of evidence demonstrates biosimilarity ([@A16]; [@A47]; [@A61]). The mechanism of action of the biologic across the different indications concerned is a key consideration.

Several biosimilars approved in Europe, such as those for filgrastim, epoetin, bevacizumab, trastuzumab, and infliximab, have been successfully approved in multiple indications on the basis of extrapolation ([@A20]; [@A60]). Similarly, in the United States, extrapolation has allowed biosimilars for adalimumab, etanercept, filgrastim, bevacizumab, trastuzumab, epoetin, and infliximab to be licensed for use in multiple indications ([@A46], [@A49], [@A50], [@A51], [@A56]).

**Interchangeability**

Interchangeability is the concept that two products can be exchanged one for another without a significant risk of harm to the patient ([@A9]; [@A41]; [@A42]; [@A45]; [@A58]). Automatic substitution is the practice by which a product other than the one prescribed is dispensed at the pharmacy level without the consent of the prescriber ([@A9]; [@A41]; [@A42]; [@A45]; [@A58]).

There are no recommendations from the EMA regarding interchangeability, and it is instead the responsibility of individual member states ([@A42]). Many of these countries have prohibited automatic substitution ([@A41]). In the United States, individual state laws will apply to interchangeability and automatic substitution ([@A41]). However, recent FDA draft guidance has stated that a biologic product may be considered interchangeable if the product \"can be expected to produce the same clinical result as the reference product in any given patient\" and \"the risk in terms of safety or diminished efficacy of alternating or switching between use of the biological product and the reference product is not greater than the risk of using the reference product without such alternation or switch\" ([@A53]). The data required to support these criteria can vary based on a number of factors, including product complexity, product-specific immunogenicity, and available postmarketing data. The FDA recommends that developers of an interchangeable medicine work with the FDA to determine a suitable product development plan needed to support demonstration of interchangeability ([@A53]). Consequently, interchangeability is approved on a case-by-case basis.

Interchangeability determinations may have implications for patients, clinicians, and health-care systems. Therefore, one suggestion is that health-care system frameworks include operational and educational guidance on biosimilars, including guidance on alternating or switching between products (e.g., for oncology drugs, the acute dosing schedule may mean that initiating treatment with a biosimilar may be more acceptable than switching therapies mid-course), communicating product changes to other health-care providers and patients, strategies to distinguish between biosimilars and originator products, and opt-out provisions ([@A13]; [@A32]).

**Pharmacovigilance**

Pharmacovigilance refers to the detection, assessment, and prevention of adverse effects after a product is launched onto the market ([@A9]; [@A13]; [@A42]; [@A45]). As with all biologics, postmarketing pharmacovigilance is critical to monitor the safety of biosimilars, particularly due to their complexity and unique manufacturing and development processes, and will take the form of risk management plans and other pharmacovigilance protocols ([@A9]; [@A13]; [@A42]; [@A45]). Advanced practice providers play an important role in the long-term monitoring and assessment of medicinal products within the clinic; thus, distinct and unique names for biosimilars will help support pharmacovigilance efforts. Furthermore, pharmacovigilance is necessary to monitor and assess rare adverse events or immunogenicity that may not be detected during the clinical trial stages ([@A9]; [@A13]; [@A42]; [@A45]). Therefore, advanced practice providers are critical to ensuring long-term patient safety in clinical practice and should report any suspected adverse events or drug reactions, as well as identify the specific product that is causing the event/reaction, whether it is the biosimilar or the originator product.

**Other Practical Considerations**

Due to the sensitivity and complexity of the biosimilar manufacturing process, awareness of a manufacturer's handling practices and history of recalls associated with product quality is essential to ensure drug efficacy and patient safety ([@A8]; [@A9]; [@A13]; [@A24]; [@A30]; [@A43]). Furthermore, biologics are often administered to patients in local hospitals or physician offices; therefore, it is important to consider the logistics for products in these settings ([@A24]). For example, proper drug storage and handling/administration, product availability, supply chain security, and the ability to discriminate between products are critical to ensure patient care, product integrity, and effective long-term safety monitoring in the clinical practice setting ([@A24]).

Manufacturer-provided support services represent another potential area of differentiation between biosimilars and originator products, or indeed between various biosimilars, including tools for reducing administrative burden, patient education offerings, and prefilled syringes to improve patient efficiencies. Therefore, in order to remain informed and provide the best possible care and treatment options to their patients, it is vital that advanced practice providers participate in pharmacy and therapeutics committees and continue to play an active role in the assessment and inclusion of biosimilar products within their local formulary. Additionally, it is important that advanced practice providers assist with ensuring that both patients and other health-care providers are made aware of any changes in treatment plans, i.e., switching from an originator product to a biosimilar, or switching between biosimilars. Furthermore, advanced practice providers should be vigilant when both biosimilars and originator products are available within their clinic to ensure appropriate safety monitoring and tracking of any potential adverse events and drug reactions, as well as to be aware of any differences in the storage or availability of these products, in order to mitigate potential issues with product quality or supply.

**Pricing**

Although biosimilars are less costly than the corresponding originator products, the discounts (reported to be approximately 30% in Europe; [@A5]) are typically not as marked down as those observed with small-molecule generic drugs. This is predominantly due to the overall cost of biosimilar development ([@A2]; [@A10]; [@A13]; [@A41]). Price regulation and reimbursement concerning biosimilars can vary between countries and, within the United States, these will vary based on the setting of administration, prescription drug coverage, and local policies ([@A2]; [@A10]; [@A13]; [@A41]). In the community setting, medication decisions are often based on cost, patient reimbursement policies, and individual insurance plans. Therefore, it is important that advanced practice providers be involved in the treatment decision-making process, are aware of when patients are on biosimilars or originator products in order to monitor for any differences in clinical responses or toxicities, and remain informed regarding the treatment choices available to their patients.

SUMMARY
=======

Biosimilars have the potential to substantially impact patient care by reducing costs and expanding access to biologic therapies. As more biosimilars are approved and become available, advanced practice providers will be at the forefront of treatment decisions involving biosimilars, addressing queries from patients and other health-care providers regarding biosimilars, and managing the successful integration of biosimilars into clinical practice. Therefore, it is important that advanced practice providers understand the developmental and regulatory process concerning biosimilars, the key practical considerations for biosimilars, and the importance of biosimilars in improving access to biologic therapies in clinical practice.
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